<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04164589</url>
  </required_header>
  <id_info>
    <org_study_id>SCENAR-EC</org_study_id>
    <nct_id>NCT04164589</nct_id>
  </id_info>
  <brief_title>EFFECTIVENESS OF THE NEUROADAPTATIVE FOR URGE INCONTINENCE</brief_title>
  <acronym>SCENAR-EC</acronym>
  <official_title>EFFECTIVENESS OF THE NEUROADAPTATIVE REGULATION TECHNIQUE FOR THE TREATMENT OF URGE INCONTINENCE AND MIXED INCONTINENCE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this clinical trials the sponsor want to assess a
      self-controlled-energo-neuroadaptative-regulation in patient with urge incontinence
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this clinical trials the sponsor want to assess a
      self-controlled-energo-neuroadaptative-regulation in patient with urge incontinence and
      mixted incontinence
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2019</start_date>
  <completion_date type="Anticipated">July 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized, single blind placebo controlled clinical trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resultant value achieved in the assessment scale of urge incontinence.</measure>
    <time_frame>2 years</time_frame>
    <description>Resultant value achieved in the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI-SF). The ICIQ-UI Short Form is a questionnaire for evaluating the frequency, severity and impact on quality of life (QoL) of urinary incontinence. Question items: Frequency or urinary incontinence; Amount of leakage; Overall impact of urinary incontinence; Self-diagnostic ítem. Scoring scale: 0-21. Higher score mean a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sandvik Test for Urinary Incontinence</measure>
    <time_frame>2 years</time_frame>
    <description>It is a severity indez score of symptoms to calculate severity of urinary incontinence in women. Scores are from 0 to 12. The higher score: the more severe the urinary incontinence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intervals between voiding</measure>
    <time_frame>2 years</time_frame>
    <description>time between voiding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of nocturia</measure>
    <time_frame>2 years</time_frame>
    <description>Frequency of nocturia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life index (Potenziani-14-CI-IO-QOL-2000 index)</measure>
    <time_frame>2 years</time_frame>
    <description>Impact of incontinence on quality of life. Scores are from 0 to 28. Slight impact in quality of life = 0-14. Higher impact in quality of life = 15-28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with the treatment (Visual analogue scale.)</measure>
    <time_frame>2 years</time_frame>
    <description>Visual analogue scale. Minimun values: 0, máximum values: 10. Higher score means a high satisfaction with the treatment received.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the response to treatment</measure>
    <time_frame>2 years</time_frame>
    <description>the duration of the response to treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Urge Incontinence</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The Neuro-Adaptative Regulation will be carried out in the regime of switched off power supply in vulvo-perineal and sacral area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The neuro-adaptative regulation will be carried out in vulvo-perineal and sacarl area.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SCENAR 1NT-02.2</intervention_name>
    <description>The neuro-adaptative regulation will be carried out in vulvo-perineal and sacral area</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Neuro-adaptative regulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Urge incontinence or mixed incontinence without urethral hypermobility

          -  Over 3 months of disease evolves.

        Exclusion Criteria:

          -  Severe physical limitations that might interfere with applying the treatment.

          -  Severe mental disorders that need pharmacology treatments that may influence in
             neuronal activity

          -  Oncological processes in the lower abdomen that had required radical surgery.

          -  Neurogenic bladder.

          -  Blockage of the bladder

          -  Vaginal infection

          -  Bladder infection or disorder of kidney function

          -  Have received, in the last year, botulinum toxin in bladder or pelvic organs.

          -  Have received pharmacological treatment for urge incontinence in the last month
             (before entry date in the trial)

          -  Be receiving pharmacological treatment for urge incontinence.

          -  Stress incontinence due to urethral hypermobility which was treatable with surgery.

          -  Pregnant women

          -  Patients with pacemarker
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alvaro Zapico-Goñi, MD</last_name>
    <phone>918878100</phone>
    <email>azapicog1@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diana Barreira, Ph</last_name>
    <phone>918878100</phone>
    <email>dbarreirahdez@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Álvaro Zapico-Goñi</name>
      <address>
        <city>Madrid</city>
        <zip>28805</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alvaro Zapico-Goñi, M.D</last_name>
      <phone>918878100</phone>
      <email>azapicog1@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 13, 2019</study_first_submitted>
  <study_first_submitted_qc>November 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2019</study_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

